Epidemiology of pathogenic Neisseria meningitidis serogroup B serosubtypes in Malta: Implications for introducing PorA based vaccines

Vaccine

Volumn 26, Issue 47, 2008, Pages 5952-5956

  Pace, David ^a   Cuschieri, Paul ^a   Galea Debono, Anthony ^a   Attard Montalto, Simon ^a  

^a MATER DEI HOSPITAL   (Malta)

Author keywords

Cross reactivity; Epidemiology; Immunogenicity; Neisseria meningitidis serogroup B; Outer membrane vesicle vaccines; Serosubtypes

Indexed keywords

EPITOPE; HEXAMEN; MENINGOCOCCUS VACCINE; NONAMEN; PORIN A; UNCLASSIFIED DRUG; VA MENGOC BC;

ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLONE; EPIDEMIC; HUMAN; INFECTION CONTROL; MALTA; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; WILD TYPE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFANT, NEWBORN; MALTA; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MIDDLE AGED; NEISSERIA MENINGITIDIS, SEROGROUP B; PORINS; PREVALENCE; SEROTYPING; YOUNG ADULT;

EID: 55049131005     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.08.059     Document Type: Article

References (40)

1. Pollard A.J., and Levin M. Vaccines for prevention of meningococcal disease. Pediatr Infect Dis J 19 4 (2000) 333-344
2. Environmental Science and Research Limited. The Epidemiology of Meningococcal Disease in New Zealand in 2006. Wellington: Ministry of Health; 2006. Available from http://www.moh.govt.nz/moh.nsf/pagesmh/6647/$File/epidemiology-of-meningococcal-disease-2006.pdf.
3. Rosenstein N.E., Perkins B.A., Stephens D.S., Popovic T., and Hughes J.M. Meningococcal disease. N Engl J Med 344 May (18) (2001) 1378-1388
4. Miller E., Salisbury D., and Ramsay M.E. Planning, registration and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20 Suppl. 1 (2001) S58-67
5. Bilukha O.O., and Rosenstein N. National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 54 May (RR-7) (2005) 1-21
6. Meningitis Research Foundation of Canada. Vaccines. Available from http://www.meningitis.ca/vaccines/meningococcal.asp.
7. Finne J., Leinonen M., and Makela P.H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 2 8346 (1983) 355-357
8. Jones D.M., and Eldridge J. Development of antibodies to meningococcal protein and lipopolysaccharide serotype antigens in healthy-carriers. J Med Microbiol 12 February (1) (1979) 107-111
9. Griffiss J.M., Brandt B.L., Broud D.D., Goroff D.K., and Baker C.J. Immune response of infants and children to disseminated infections with Neisseria meningitidis. J Infect Dis 150 July (1) (1984) 71-79
10. Van der Ley P., Heckels J.E., Virji M., Hoogerhout P., and Poolman J.T. Topology of outer membrane porins in pathogenic Neisseria spp. Infect Immun 59 (1991) 2963-2971
11. Clarke S.C., Diggle M.A., Molling P., Unemo M., and Olcen P. Analysis of PorA variable region 3 in meningococci: implications for vaccine policy?. Vaccine 21 (2003) 2468-2473
12. Idänpään-Heikkilä I., Høiby E.A., Chattopadhyay P., Airaksinen U., Michaelsen T.M., and Wedege E. Antibodies to meningococcal class 1 outer-membrane protein and its variable regions in patients with systemic meningococcal disease. J Med Microbiol 43 November (5) (1995) 335-343
13. Holst J., Feiring B., Fuglesang J.E., Høiby E.A., Nøkleby H., Aaberge I.S., et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 21 January (7-8) (2003) 734-737
14. Rouppe van der Voort E.M., van der Ley P., van der Biezen J., George S., Tunnela O., van Dijken H., et al. Specificity of human bactericidal antibodies against PorA P1.7, 16 induced with a hexavalent meningococcal outer membrane vesicle vaccine. Infect Immun 64 (1996) 2745-2751
15. Sierra G.V., Campa H.C., Varcacel N.M., Garcia I.L., Izquierdo P.L., Sotolongo P.F., et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 14 2 (1991) 195-207 [discussion 208-110]
16. De Moraes J.C., Perkins B.A., Camargo M.C., Hidalgo N.T., Barbosa H.A., Sacchi C.T., et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo Brazil. Lancet 340 (1992) 1074-1078
17. Cruz C., Pavez G., Aguilar E., Grawe L., Cam J., Mendez F., et al. Serotype-specific outbreak of group B meningococcal disease in Iquique, Chile. Epidemiol Infect 105 (1990) 119-126
18. Boslego J., Garcia J., Cruz C., Zollinger W., Brandt B., Ruiz S., et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine 13 (1995) 821-829
19. Bjune G., Høiby E.A., Grønnesby J.K., Arnesen O., Fredriksen J.H., Halstensen A., et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338 November (8775) (1991) 1093-1096
20. O'Hallahan J., Lennon D., and Oster P. The strategy to control New Zealand's epidemic of group B meningococcal disease. Pediatr Infect Dis J 23 Suppl. 12 (2004) S293-S298
21. Claassen I., Meylis J., van der Ley P., Peeters C., Brons H., Robert J., et al. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 14 July (10) (1996) 1001-1008
22. Van der Ley P., van der Biezen J., and Poolman J.T. Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine. Vaccine 13 March (4) (1995) 401-407
23. Census of Population and Housing 2005, Population, vol. 1. Valletta: National Statistics Office; 2007. Available from http://www.nso.gov.mt/docs/Census2005_Vol1.pdf.
24. EU-IBIS Network. Invasive Neisseria meningitidis in Europe 2003/2004. London: Health Protection Agency; 2006. Available from www.euibis.org.
25. Greenwood B.M., Bradley A.K., and Wall R.A. Meningococcal disease and season in sub-Saharan Africa. Lancet 2 (1985) 829-830
26. World Health Organisation. Control of Epidemic Meningococcal Disease: WHO Practical Guidelines. 2nd ed. Geneva, Switzerland: World Health Organisation; 1998. Available from http://www.who.int/csr/resources/publications/meningitis/whoemcbac983.pdf.
27. Disease Surveillance Unit, Department of Public Health, Ministry of Health, the Elderly and Community Care, Government of Malta, 2006. Annual Report 2005. Available from: http://www.health.gov.mt/dsu/reports/index.htm.
28. Tappero J.W., Lagos R., Ballesteros A.M., Plikaytis B., Williams D., Dykes J., et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 281 April (16) (1999) 1520-1527
29. Morley S.L., Cole M.J., Ison C.A., Camaraza M.A., Sotolongo F., Anwar N., et al. Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants. Pediatr Infect Dis J 20 November (11) (2001) 1054-1061
30. Peeters C.C., Rümke H.C., Sundermann L.C., Rouppe van der Voort E.M., Meulenbelt J., Schuller M., et al. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine 14 July (10) (1996) 1009-1015
31. Cartwright K., Morris R., Rümke H., Fox A., Borrow R., Begg N., et al. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 17 June (20-21) (1999) 2612-2619
32. de Kleijn E.D., de Groot R., Labadie J., Lafeber A.B., van den Dobbelsteen G., van Alphen L., et al. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age. Vaccine 18 February (15) (2000) 1456-1466
33. Van den Dobbelsteen G., van Dijken H., Hamstra H.-J., Ummels R., Van Alphen L., and Peter Van der Ley P. From HexaMen to NonaMen: expanding a multivalent PorA-based meningococcal outer membrane vesicle vaccine. Proceedings of the 14th International Pathogenic Neisseria Conference (2004) 153 [Abstract]
34. Boutriau D., Poolman J., Borrow R., Findlow J., Domingo J.D., Puig-Barbera J., et al. Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents. Clin Vaccine Immunol 14 January (1) (2007) 65-73
35. Mothershed E.A., Sacchi C.T., Whitney A.M., Barnett G.A., Ajello G.W., Schmink S., et al. Use of real-time PCR to resolve slide agglutination discrepancies in serogroup identification of Neisseria meningitidis. J Clin Microbiol 42 1 (2004) 320-328
36. Maiden M.C.J., Bygraves J.A., McCarvil J., and Feavers I.M. Identification of meningococcal serosubtypes by polymerase chain reaction. J Clin Microbiol (1992) 2835-2841
37. Nissen M.D., Marshall H.S., Richmond P., Lambert S.B., Roberton D., Gruber W.C., et al. A randomized, placebo-controlled, double-blind, phase 1 trial of ascending doses of meningococcal group B rLP2086 vaccine. 26th Annual Meeting of the European Society for Paediatric Infectious Diseases-ESPID. Graz, Austria, May 13-17 (2008)
38. Weynants V., Goraj K., Feron C., Bos M., Denoel P., Verlant V., et al. Combination of minor outer membrane proteins inducing bactericidal antibodies in mice. 15th International Pathogenic Neisseria Conference-IPNC. North Queensland, Australia, September 10-15 (2006) [Abstract P8.3.16]
39. Giuliani M.M., Adu-Bobie J., Comanducci M., Aricò B., Savino S., Santini L., et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 103 29 (2006) 10834-10839
40. Miller E., Pollard A.J., Borrow R., Findlow J., Dawson T., Morant A., et al. Safety and immunogenicity of Novartis meningococcal serogroup B vaccine after three doses administered in infancy. 26th Annual Meeting of the European Society for Paediatric Infectious Diseases-ESPID. Graz, Austria, May 13-17 (2008)